This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For additional information about Harpoon Therapeutics, please visit Cautionary Note on Forward-looking Statements Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Using its proprietary Tri-specific T cell Activating Construct (TriTAC ®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Additionally, I am confident Banmeet’s breadth of translational medicine experience and ability to successfully lead development teams will provide critical value as we look to advance our multiple T cell engager programs.” “It is exciting to have an HR leader of Wendy’s caliber onboard as we continue to evolve as an organization. “We are pleased to welcome Wendy and Banmeet to the Harpoon leadership team,” said Julie Eastland, President and CEO of Harpoon Therapeutics. He previously served in multiple leadership and scientific roles at NantKwest, Astellas (Agensys) and Genentech. Anand served as Vice President, Head of Nonclinical Development/Clinical Pharmacology at Molecular Templates. Anand brings more than 18 years of experience leading translational research and implementing drug discovery and development strategies for unmet medical needs across multiple therapeutic areas and clinical modalities. She previously served as Vice President, Human Resources at Gilead Sciences and, earlier in her career, at Bio-Rad Laboratories.ĭr. She comes to Harpoon from IDbyDNA where she served as Vice President, Head of People & Culture.

Chang has over 20 years of human resources experience in life sciences and an extensive background in aligning talent with organizations’ overall vision and direction. Anand bring deep experience to their respective roles, enhancing strategic and scientific guidance within the organization to drive the company forward in a year of anticipated clinical advancements across Harpoon’s portfolio.

(Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. Appointments named for two key executive leadership positions in human resources and translational medicine.

Harpoon therapeutics